ReviewCellular and molecular life sciences : CMLS2016
The role of the prolactin/vasoinhibin axis in rheumatoid arthritis: an integrative overview.
Review in Cellular and molecular life sciences : CMLS, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 38 citations in OpenAlex.
- Increase in serum prolactin levels as a potential biomarker in Crohn's disease: a prospective cohort study.Frontiers in medicine · 2026Article
- Vasoinhibin is Generated by the Renin-angiotensin System.Endocrinology · 2025Article
- The emerging role of vascular endothelial cell-mediated angiogenesis in the imbalance of RA synovial microenvironment and its clinical relevance.Frontiers in pharmacology · 2025Review
- Prolactin: structure, receptors, and functions.Reviews in endocrine & metabolic disorders · 2024Review
- Exploring the association of serum prolactin with serum glucose levels and clinical findings in a cohort of patients with early rheumatoid arthritis.Advances in rheumatology (London, England) · 2024Observational
- Deciphering the Involvement of Chronic Inflammation in Osteoarthritis: Evaluation of Complement 3 and Cathepsin D in Osteoarthritic Patients-A Retrospective Case Study.Journal of pharmacy & bioallied sciences · 2024Article
- Immunometric and functional measurement of endogenous vasoinhibin in human sera.Frontiers in endocrinology · 2024Article
- Overview of Rheumatoid Arthritis and Scientific Understanding of the Disease.Mediterranean journal of rheumatology · 2023Review
- The role of prolactin/vasoinhibins in cardiovascular diseases.Animal models and experimental medicine · 2023Review
- Association between sexual maturation and anterior disc displacement of temporomandibular joint in adolescents aged 13-14 years.Clinical oral investigations · 2022Article
- Vasoinhibin is Generated and Promotes Inflammation in Mild Antigen-induced Arthritis.Endocrinology · 2022Article
- Dual Roles of Prolactin and Vasoinhibin in Inflammatory Arthritis.Frontiers in endocrinology · 2022Review
- Prediction and Verification of the Major Ingredients and Molecular Targets ofFrontiers in pharmacology · 2021Article
- The Emerging Roles of Endocrine Hormones in Different Arthritic Disorders.Frontiers in endocrinology · 2021Review
- Global Deletion of the Prolactin Receptor Aggravates Streptozotocin-Induced Diabetes in Mice.Frontiers in endocrinology · 2021Article
- Vasoinhibin reduces joint inflammation, bone loss, and the angiogenesis and vasopermeability of the pannus in murine antigen-induced arthritis.Laboratory investigation; a journal of technical methods and pathology · 2020Article
- Hyperprolactinaemia.Journal of clinical medicine · 2019Review
- Review
- PRL -1149T allele (rs1341239) is associated with decreased risk of rheumatoid arthritis in population from southern Mexico: analysis of mRNA expression and PRL serum levels.Clinical rheumatology · 2019Article
- Regulator of Angiogenesis and Vascular Function: A 2019 Update of the Vasoinhibin Nomenclature.Frontiers in endocrinology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic, autoimmune, inflammatory disease destroying articular cartilage and bone. The female preponderance and the influence of reproductive states in RA have long linked this disease to sexually dimorphic, reproductive hormones such as prolactin (PRL). PRL has immune-enhancing properties and increases in the circulation of some patients with RA. However, PRL also suppresses the immune system, stimulates the formation and survival of joint tissues, acquires antiangiogenic properties upon its cleavage to vasoinhibins, and protects against joint destruction and inflammation in the adjuvant-induced model of RA. This review addresses risk factors for RA linked to PRL, the effects of PRL and vasoinhibins on joint tissues, blood vessels, and immune cells, and the clinical and experimental data associating PRL with RA. This information provides important insights into the pathophysiology of RA and highlights protective actions of the PRL/vasoinhibin axis that could lead to therapeutic benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.